Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, French Startup Tie Up on Gut Bacteria-Derived Drugs for GI Disorders
January 7, 2016
- Selexipag Now Available in US: Nippon Shinyaku
January 6, 2016
- Generic Use Rate at 54.7% in July-September 2015: JGA
January 6, 2016
- Fuji Pharma Licenses Nesp Biosimilar from S. Korean Firm
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Torii Files NDA for Allergen Immunotherapy Tablet for Cedar Pollinosis
January 5, 2016
- ASKA Files Rifaximin for Hepatic Encephalopathy
December 25, 2015
- Bristol-Myers Files Elotuzumab for Relapsed, Refractory Multiple Myeloma in Japan
December 25, 2015
- FDA OKs Selexipag Originated by Nippon Shinyaku
December 24, 2015
- MSD Seeks Japan Approval for Pembrolizumab for Melanoma
December 24, 2015
- Israel’s Pluristem Therapeutics to Enter into Japanese Regenerative Medicine Market
December 24, 2015
- Lacosamide Reduces Partial-Onset Seizures in PIII: Daiichi Sankyo, UCB
December 22, 2015
- Shionogi, Mundipharma Seal Agreement on Ethical Isodine Products
December 22, 2015
- CSL Behring Files rIX-FP for Hemophilia B Treatment in Japan
December 22, 2015
- PeptiDream Ties Up with Genentech for Peptide Discovery
December 22, 2015
- Eisai to Transfer Manufacturing Subsidiary to Alfresa
December 21, 2015
- 80% Target for Generics Presents “Business Opportunity” for Alfresa Fine Chemical: Pres. Miyadera
December 21, 2015
- Acucela Establishes Japanese Subsidiary to Strengthen Business in Japan
December 21, 2015
- BMKK, Ono Initiate Multinational PIIIb Study of Orencia in Japan
December 21, 2015
- Ohara Files Japan NDA for ALL Drug Crisantaspase
December 18, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…